Olanzapin

Olanzapin
(IUPAC) ime
	2-metil-4-(4-metil-1-piperazinil)-10H-tieno[2,3-b][1,5]benzodiazepin
Klinički podaci
Robne marke	Zipreksa
AHFS/Drugs.com	Monografija
MedlinePlus	a601213
Identifikatori
CAS broj	132539-06-1
ATC kod	N05AH03
PubChem	4585
DrugBank	DB00334
ChemSpider	10442212
UNII	N7U69T4SZR
KEGG	D00454
ChEBI	CHEBI:7735
ChEMBL	CHEMBL715
Hemijski podaci
Formula	C17H20N4S
Mol. masa	312,439
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3 ; Key: KVWDHTXUZHCGIO-UHFFFAOYSA-N
Fizički podaci
Tačka topljenja	195 °C (383 °F)
Rastvorljivost u voda	Nije rastvoran u vodi mg/mL (20 °C)
Farmakokinetički podaci
Bioraspoloživost	87%
Metabolizam	Hepatički (direktna glukuronidacija oksidacije posredovane CYP-om)
Poluvreme eliminacije	21–54 sata
Izlučivanje	urin 57%, izmet 30%
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	℞ Prescription only
Način primene	oralno, intramuskularno

Olanzapin (Zipreksa ili u kombinaciji sa fluoksetinom Simbiaks) je atipični antipsihotik, koji je FDA odobrila za tretman šizofrenije i bipolarnog poremećaja.^[7] Olanzapin je strukturno sličan sa klozapinom, ali je klasifikovan kao tienobenzodiazepin. Olanzapin proizvodi i prodaje farmaceutska kompanija Ilaj Lili end kompani. Lek je poprimio generički status 2011. Prodaja Zipreksa je 2008. bila $2.2 milijarde u SAD-u, i $4.7 milijarde globalno.^[8]

Farmakologija

Olanzapin ima veći afinitet za 5-HT₂ serotoninske receptore nego D₂ dopaminske receptore. Afiniteti u donjoj list su konstante disocijacije (K_i, nM). Olanzapin se vezuje kao antagonist/inverzni agonist za sledeće receptore^[9]:

dopaminski D₁: 31
dopaminski D₂: 11
dopaminski D₄: 27
serotoninski 5-HT_2A: 4
serotoninski 5-HT_2C: 11
serotoninski 5-HT₃: 57
muskarinski M₁: 26
adrenergički alfa₁: 19
histaminski H₁: 7

Hemija

Olanzapin se može pripremiti počevši od malononitrila i propionaldehida:^[10]

Povezano

Antipsihotik

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Burton, Michael E.; Shaw, Leslie M.; Schentag, Jerome J.; Evans, William E. (1. 5. 2005.). Applied Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug Monitoring. Lippincott Williams & Wilkins; Fourth Edition edition. str. 815. ISBN 978-0-7817-4431-7.
↑ „Olanzapine Prescribing Information” (PDF). Eli Lilly and Company. 19. 3. 2009.. Pristupljeno 6. 9. 2009.
↑ „Lilly 2008 Annual Report” (PDF). Lilly. 2009. Arhivirano iz originala na datum 2011-10-01. Pristupljeno 6. 8. 2009.
↑ Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. (1996). „Radioreceptor binding profile of the atypical antipsychotic olanzapine.”. Neuropsychopharmacology. 14 (2): 87–96. DOI:10.1016/0893-133X(94)00129-N. PMID 8822531.
↑ US 5229382, Šablon:Cite patent/authors, "2-methyl-thieno-benzodiazepine"

Literatura

Spoljašnje veze

	Portal Medicina
	Portal Hemija

Korisničke informacije

MedLibrary.org - 'Information on Zyprexa and How to Use It, Precautions and Other Medications to Avoid While Taking
NIH.gov - 'Olanzapine (Systemic)' Drug Informationn
Esoteric Drugs Olanzapine Arhivirano 2012-11-01 na Wayback Machine-u

Kontroverze

nytyimes.com - Lilly Settles With 18,000 Over Zyprexa, Alex Berenson, New York Times (December 17, 2006)

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[6] Burton, Michael E.; Shaw, Leslie M.; Schentag, Jerome J.; Evans, William E. (1. 5. 2005.). Applied Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug Monitoring. Lippincott Williams & Wilkins; Fourth Edition edition. str. 815. ISBN 978-0-7817-4431-7.

[olanzapinepi-7] „Olanzapine Prescribing Information” (PDF). Eli Lilly and Company. 19. 3. 2009.. Pristupljeno 6. 9. 2009.

[8] „Lilly 2008 Annual Report” (PDF). Lilly. 2009. Arhivirano iz originala na datum 2011-10-01. Pristupljeno 6. 8. 2009.

[9] Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. (1996). „Radioreceptor binding profile of the atypical antipsychotic olanzapine.”. Neuropsychopharmacology. 14 (2): 87–96. DOI:10.1016/0893-133X(94)00129-N. PMID 8822531.

[10] US 5229382, Šablon:Cite patent/authors, "2-methyl-thieno-benzodiazepine"

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]